Search the Newsreel

Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary

Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, …

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results …

Willdan Group (WLDN) Tops Q2 Earnings and Revenue Estimates

Willdan Group (WLDN) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Earnings call transcript: Willdan Group tops Q2 2026 estimates, shares jump 14%

Willdan Group soars 13% on earnings beat, raised guidance

Willdan Group Inc. (NASDAQ:WLDN) saw its shares surge 13.3% after reporting second-quarter results that significantly surpassed analyst expectations, with adjusted EPS of $2.07 and revenue of $117.2 million. The company also raised its fiscal 2026 financial guidance, projecting adjusted EPS between $5.00 and $5.15 …

Willdan Group (WLDN) Stock Rises on Q2 2026 Earnings

Willdan Group (WLDN) reported a strong second quarter for 2026, with revenue significantly exceeding estimates and profitability improving sharply. The company saw substantial increases in revenue, net income, and diluted earnings per share, leading to a 13.75% rise in its stock after market close. …

Earnings Flash (WLDN) Willdan Group, Inc. Posts Q2 Adjusted EPS $2.07 per Share

Willdan Group, Inc. (WLDN) announced its Q2 adjusted EPS of $2.07 per share. The company also reported Q2 revenue of $231.0M. Willdan Group is a technical services company focusing on energy and infrastructure solutions.

Willdan Q2 FY2026 earnings: Energy demand drives 23.5% net revenue growth

Willdan (Nasdaq: WLDN) reported strong Q2 FY2026 earnings, with net revenue growing 23.5% to $117.2 million and adjusted EBITDA rising 50.6% to $33.0 million, primarily driven by demand in its Energy segment. The company increased its FY2026 financial targets, reflecting continued growth expectations, although …

Willdan Group (NASDAQ: WLDN) lifts Q2 profit and raises 2026 targets

Willdan Group (NASDAQ: WLDN) reported strong second-quarter 2026 results, with contract revenue reaching $231.0 million, a 33.2% increase year-over-year, and net income up 57.7% to $24.3 million. The company also raised its fiscal year 2026 financial targets, projecting net revenue between $415 million and …

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Celldex reported a wider net loss of $

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M

Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets …

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's …

Willdan Group faces earnings test on data center growth bets

Willdan Group Inc. is set to announce its second-quarter results, with analysts expecting $1.34 earnings per share on $102.3 million revenue. Investors will be closely watching the performance of its data center infrastructure business, projected to be a significant growth driver, and the sustainability …

Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M

Willdan Group (NASDAQ:WLDN) Issues Quarterly Earnings Results

Willdan Group (WLDN) Earnings Date and Reports 2026

Celldex Therapeutics earnings up next as Phase III data looms By Investing.com

Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall …

Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com

Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, …

Alldigi Tech - Top 10 stocks with 7-14% dividend yields. Do you own any?

Alldigi Tech Standalone June 2026 Net Sales at Rs 84.90 crore, up 1.82% Y-o-Y

Wedbush Sticks to Its Buy Rating for Willdan Group (WLDN)

Wedbush maintained a Buy rating on Willdan Group (WLDN) with a price target of $130.00, citing the company's recent earnings report which showed increased revenue and net profit compared to the previous year. Despite the positive analyst outlook, corporate insider sentiment on the stock …

Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared …

Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high …

NatWest profits up by a fifth after AI-led tech drive and wealth focus

NatWest has become the latest high street bank to report a bigger-than-expected jump in earnings, after growing its wealth arm and an AI-led tech drive. The British banking group made an operating pre-tax profit of £4.3 billion for the six months to the end …

Willdan Group Inc (WLDN) Financial Health: Profitability & Balance Sheet Analysis

Willdan Group Inc (WLDN) has a financial score of 6.28, placing it 127th out of 159 in the Professional & Commercial Services industry, indicating robust financial status but average operating efficiency. The company reported a 1.79% year-over-year increase in its latest quarterly revenue to …

Lloyds Banking Group PLC (LYG) (H1 2026) Earnings Call Highlights: Strong Profit Growth and ...

This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lloyds Banking Group PLC (NYSE:LYG) reported strong H1 2026 financial performance with a 17.1% return …

BlackRock (WLDN) discloses 8.0% beneficial stake in Willdan common stock

BlackRock, Inc. has filed an Amendment No. 8 disclosing a beneficial ownership of 1,209,993 shares, representing 8.0% of Willdan Group, Inc.'s common stock as of June 30, 2026. BlackRock holds sole voting power over 1,187,067 shares and sole dispositive power over all 1,209,993 shares. …

Lloyds Bank plc 2026 half year results

LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Lloyds Bank plc 2026 half year results 30 July 2026 Member of the Lloyds Banking Group CONTENTS Forward-looking statements Condensed consolidated income statement (unaudited) 1 Condensed consolidated balance sheet (unaudited) 1 Financial review 2 Risk management Principal …

Willdan Group (WLDN) Expected to Post Quarterly Earnings on Thursday

Lloyds Banking Aktie: Gewinnplus, Kurs im Minus

Lloyds Banking Group CEO on Earnings, 2030 Plan

Lloyds Banking Group Chief Executive Officer Charlie Nunn speaks on Bloomberg Television after the lender's second-quarter earnings beat estimates and the bank unveiled a blueprint to help boost non-banking revenues by 2030. "We've got some exciting growth to do," Nunn says. View Comments

Lloyds targets another £2bn cost-cutting as half-year profit jumps by 23%

Lloyds Banking Group has revealed its profits have jumped by nearly a quarter, as its boss unveiled a new four-year plan to deepen the use of AI and further digitalise the bank to help drive a fresh £2 billion of cost cuts. The banking …

Stempoint Capital LP Purchases New Shares in Celldex Therapeutics, Inc. $CLDX

Lloyds-Gewinn steigt um gut ein Fünftel

Willdan Group Inc (WLDN) Risk Assessment: Volatility, Financial Risk & Investment Risk

Willdan Group Inc (WLDN) has a current risk assessment score of 5.77, ranking 81 out of 160 in the Professional & Commercial Services industry, indicating a neutral impact from the U.S. Dollar Index. With a beta of 1.10, the stock tends to outperform in …

Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a …